D-Cycloserine Augmentation of Exposure and Response Prevention Treatment for Obsessive-Compulsive Disorder

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

We propose to undertake an initial study of DCS to determine whether it has any short-term clinical benefits when added to standard ERP therapy in adults with OCD.

• Phase: Phase 2

Details

• Lead Sponsor: University of Florida
• Collaborator: Obsessive Compulsive Foundation
• Treatments: Cycloserine

Criteria

Inclusion Criteria:

1. a principal diagnosis of OCD assigned at pre-treatment, derived from the ADIS-IV, with a clinical severity rating of 4 or above;

2. 18-65 years of age; and,

3. an IQ of ³ 80.

Exclusion Criteria:

1. positive diagnosis of schizophrenia, other psychotic disorder, pervasive developmental disorder, organic brain syndrome, or mental retardation;

2. do not speak English;

3. are unwilling to attend twice weekly sessions; or,

4. is pregnant, breast feeding a child, or attempting to become pregnant (see below rationale)